$-0.45 EPS Expected for Rhythm Pharmaceuticals, Inc. (RYTM) on June, 11

May 17, 2018 - By Richard Doty

On June, 11. Investors wait Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) to announce its quarterly earnings, Faxor reports. After $-0.41 EPS report last quarter, Wall Street now predicts 9.76 % negative EPS growth of Rhythm Pharmaceuticals, Inc.. RYTM touched $30.78 during the last trading session after $0.94 change.Rhythm Pharmaceuticals, Inc. is after having 0.00% since May 17, 2017. RYTM has 145,865 volume or 44.87% up from normal. The stock underperformed the S&P 500 by 11.55%.

Rhythm Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes peptide therapeutics for the treatment of rare genetic disorders of obesity in the United States.The firm is valued at $847.00 million. The Company’s lead product candidate is Setmelanotide, a melanocortin-4 receptor agonist that is in Phase III clinical trials for treating POMC deficiency obesity and leptin receptor deficiency obesity; and Phase II clinical trials for treating Bardet-Biedl syndrome, Alstr??m syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders.Currently it has negative earnings. The firm was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015.

More recent Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) news were brought out by Nasdaq.com, Nasdaq.com and Globenewswire.com. The first one has “Rhythm Pharmaceuticals Announces Nature Medicine Publication of Longer-Term Data from Phase 2 Study of …” as a title and was brought out on May 09, 2018. The next is “Rhythm Pharmaceuticals to Present at the Bank of America Merrill Lynch 2018 Health Care Conference” on May 09, 2018. And last was brought out on May 14, 2018, called “Rhythm Pharmaceuticals Reports First Quarter 2018 Financial Results”.

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.